Let-7e enhances the radiosensitivity of colorectal cancer cells by directly targeting insulin-like growth factor 1 receptor.


Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
07 2019
Historique:
received: 23 09 2018
accepted: 22 10 2018
pubmed: 6 12 2018
medline: 12 5 2020
entrez: 6 12 2018
Statut: ppublish

Résumé

Abnormal expression of various microRNAs (miRNAs), as regulators of biological signaling pathways, has a strong association with cancer resistance to chemotherapy and radiotherapy. The let-7 family of miRNAs as tumor suppressors have shown to be downregulated in different types of human malignancies including colorectal cancer (CRC). However, the biological function of let-7 members in the processes of resistance to radiation in CRC has not yet been completely elucidated. Insulin-like growth factor 1 receptor (IGF-1R) signaling pathway is amplified in CRC and leads to its progression, development, and also radiation resistance. So, it seems like an attractive target for anticancer therapy. In this study, by using bioinformatics analysis, it has been revealed that IGF-1R is a direct target of the let-7e member. Consistent with this, we identified that increased levels of let-7e in CRC cells reduced IGF-1R protein level and subsequently its downstream signaling pathways, which resulted in the G1 cell cycle arrest and a significant reduction in the proliferation, survival and also resistance to radiation of CRC cells. Altogether, these results suggested that let-7e by targeting the IGF-1R signaling pathway might serve as therapeutics in anticancer therapy.

Identifiants

pubmed: 30515804
doi: 10.1002/jcp.27742
doi:

Substances chimiques

MicroRNAs 0
mirnlet7 microRNA, human 0
Receptor, IGF Type 1 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10718-10725

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Pouria Samadi (P)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Saeid Afshar (S)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Razieh Amini (R)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Rezvan Najafi (R)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Ali Mahdavinezhad (A)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Abdolazim Sedighi Pashaki (A)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Mohammad Hadi Gholami (MH)

Mahdieh Radiotherapy and Brachytherapy Charitable Center, Hamadan, Iran.

Massoud Saidijam (M)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH